All protocols
Weight Loss

AOD-9604 Peptide Protocol & Dosing

Updated 2mo ago 6 min read 145+ helpful Calculator
Validity Score

Validity Score

31 Speculative
Evidence 27
Community 70
Completeness 57
Actionability 60
Coverage 100
Penalty -18

This score combines formal evidence, page completeness, calculator readiness, and community convergence.

What it is

AOD-9604 is a growth-hormone fragment studied for lipid metabolism and body-fat research.

Evidence boundary

Investigational / limited human evidence.

Trial evidence

  • PMID 24124033 — AOD-9604 does not influence the WADA hGH isoform immunoassay.
  • PMID 25208511 — Detection and in vitro metabolism of AOD9604.
  • PMID 25382550 — Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.
  • PMID 11713213 — The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.

Preparation and measurement

Reconstitution: 10 mg vial + 2 mL BAC = 5 mg/mL.

Concentration matches.

Reference schedule

Reference schedule
PhaseDoseDraw / measureFrequencyWeekly total
Weeks 1–4 (titration)300 mcg6 U (0.06 mL)Once daily2.1 mg/week
Weeks 5–12 (target)500 mcg10 U (0.1 mL)Once daily3.5 mg/week

Weeks 1–4 (titration)

Dose
300 mcg
Draw / measure
6 U (0.06 mL)
Frequency
Once daily
Weekly total
2.1 mg/week

Weeks 5–12 (target)

Dose
500 mcg
Draw / measure
10 U (0.1 mL)
Frequency
Once daily
Weekly total
3.5 mg/week

Weekly totals apply only during the active phase.

Titration rules

  • Light (250 mcg/day): Conservative starting dose for tolerability assessment.

  • Standard (500 mcg/day): Common research dose. Morning fasted dosing is common.

  • Higher (1000 mcg/day): Used in some Phase 2 trials. May produce a stronger lipolytic effect.

  • Timing: Pre-fasted morning injection followed by 30–60 min of light cardio amplifies the lipolytic window. Some protocols use an additional pre-workout dose.

  • Appetite and body composition

  • Tolerability

  • Injection-site reactions

Practical rules

  • Keep the schedule tied to the collected notes, not a broad claim.
  • Use calorie control and training if body-fat loss is the goal.
  • Rotate sites.
Was this protocol helpful?
Share via
Supply & lot verification Availability and batch-linked COA records for AOD-9604 Peptide Protocol & Dosing are tracked with the current supplier listings. View availability & COA →

Dosing Calculator

10 mg + 2 mL BAC · week 1 300 mcg
LIVE CALCULATIONvolume / concentration / draw
RP–CALC–01
DRAW AMOUNT6 units0.06 mL · U-100
Draw 6 units, equivalent to 0.06 milliliters.
Concentration5 mg/mL
Selected dose0.3 mg (300 mcg) = 6 units
Enter a desired amount in milligrams or micrograms.
05 Standard amounts
1–10 mg · 0.5 mg steps
06 Suggested doses Select a row
1 unit = 0.01 mL on a U-100 syringe. Values retain decimal precision; visual marks are not silently snapped.
07 cycle summary

Vials required for Cycle

Estimate how much material you need for a full cycle, including cycle length and the number of cycles you plan to run.

Cycle total —
Total required vials —
Total reconstitution —
Total BAC water —
08 projected levels

How the draws stack up

A first-order model of depot absorption and elimination, run on the draws and cadence above. Pick the half-life from whatever your own source documents — this page does not assume one per compound. A planning sketch — not a prediction for any compound or any individual.

Half-life

Modelled level across the cycle. Each spike is one draw.

Accumulation—steady state vs one draw
Peak-to-trough—inside one interval
Steady state—about 4 half-lives
Draws modelled—at this cadence
Vial yieldat the selected amount
Draws per vial—
Lasts—
Volume used—
Limiting factor—
Water matrixsame vial, same amount
WaterStrengthDraw
0.5 mL——
1 mL——
2 mL——
3 mL——
5 mL——

Research Protocols

Keep up to date with latest protocols, updates and offers

An occasional email when a new protocol lands or an existing one is revised. No more than once a month.